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Regarding “Stroke after varicose vein foam
injection sclerotherapy”
We read with great interest Forlee et al’s report of a patient
who experienced an ischemic stroke moments after undergoing
foam injection sclerotherapy for treatment of varicose veins.1 The
patient was later determined to have a patent foramen ovale. We
commend the authors for having the presence of mind to perform
a carotid duplex scan immediately to reveal what no doubt were
intracarotid bubbles resulting from the foam injection. We note
that the patient received a total of 20 mL of polidocanol foam
prepared by the double syringe method using room air.
We previously demonstrated, using an in vivo model of arte-
riolar embolization after polidocanol microfoam sclerosant admin-
istration, that two prominent—and potentially controllable—
features of foammanufacture contribute to the number and size of
bubbles present as well as the resultant duration of blood flow
obstruction that is caused by the intravascular gas load.2 We found
that foam made with room air, rather than a gas admixture com-
prised of carbon dioxide and oxygen, was directly associated with
increased bubble number and size and caused the longest obstruc-
tion of blood flow. We attribute this to the difference in nitrogen
gas content, as nitrogen is far less soluble and diffusible in tissues
than are metabolic gases. We also found that bubbles made by the
double syringe technique were larger than those created using
mechanisms specifically engineered to dispense microfoams having
a highly controlled bubble size distribution.
We are relieved that the patient recovered significantly, but we
are not surprised by this report of a patient with a patent foramen
ovale experiencing a stroke after foam injection sclerotherapy.
Although we do not think that more careful attention to patient
cardiac anatomy through echocardiographic screening is an effec-
tive means of improving patient safety for this treatment, we do
believe that our previous findings regarding gas content and foam
formation and this case report illustrate the need to change clinical
practice regarding what is injected, and not into whom, to assure
procedural safety.
David M. Eckmann, PhD, MD
Shunji Kobayashi, MD, PhD
Department of Anesthesiology and Critical Care
University of Pennsylvania
Philadelphia, Pennsylvania
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Reply
We would like to thank Dr Morrison and Dr Eckmann and
their colleagues for the interest they have shown and the important
points they raise in response to our recent case report.1
The great saphenous vein was cannulated first in order to
minimize the delay between foam production and injection. Foam
was produced using the Tessari method, with a 4:1 air-to-liquid
ratio. Half the volume of foam was injected with the leg on the
level, while compressing the saphenofemoral junction. The leg was
then elevated and the rest of the foam was injected and massaged
into the targeted veins using ultrasound guidance. Compression
stockings were applied with the leg elevated.
With regard to the volume of foam used, we note that in Dr
Morrison’s study using different volumes of foam, our patient
would have been classified in the “low volume” group. Juan
Cabrera, the creator of the patented polidocanol foam, writes that
volumes of 20 mL to 100 mL of foam can be safely used.2 There is,
however, a lack of consensus regarding the optimal volume, and
the European Consensus statement recommends limiting volumes
to 8 mL per treatment using the Tessari method.3
Given the high prevalence of a patent foramen ovale in the
general population, it is surprising that more events have not been
reported. This would imply that most are small and hemodynam-
ically insignificant. We agree that screening before foam injection
would be impractical and probably unnecessary.
Carbon dioxide is absorbed faster than air in the body and has
been shown to produce a foam that degrades quicker.4 The tran-
sient visual symptoms reported in the literature5 are possibly due to
small amounts of air embolism. An argument could thus be made
for carbon dioxide to be used as the carrier gas.
We agree with Drs Eckmann and Kobayashi that the quality of
foam produced is very important, not only with regard to safety but
also efficacy of the procedure. For maximum stability, the size of
the bubbles in the microfoam should ideally be 100m, spheri-
cal, and of uniform size.6 With lack of uniformity in the size of the
bubbles, La Place’s Law (t p/r) dictates that the smaller bubbles
will empty into the bigger bubbles, resulting in larger bubbles with
an increased potential for the air-block effect. Although the Tessari
and other methods have been shown to be effective in producing a
foam that meets these criteria, it is difficult to accurately regulate or
measure bubble size and quality of foam in the clinical setting. This
may be a strong argument for the use of the standardized, com-
mercially produced microfoam preparation when treating varicose
veins.
Foam sclerotherapy has been shown to be safe and efficacious.
Our report describes a rare, but potentially life threatening com-
plication of this treatment.
Martin V. Forlee, FCS (SA)
Mary Paula Colgan, MD
Prakash Madhavan, FRCS (Ed)
Dermot J. Moore, MD
Gregor D. Shanik, MD
St James’s Vascular Institute
Dublin, Ireland
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Regarding “Preservation of infected and exposed
vascular grafts using vacuum assisted closure without
muscle flap coverage”
We congratulate Dosluoglu et al for their excellent results
using vacuum-assisted closure (VAC) therapy for the preservation
of infected and exposed bypass grafts (J Vasc Surg 2005;42:989-
92). We have used VAC therapy for 5 years with highly satisfac-
tory results in similar cases.
However, we recently experienced anastomotic disruption
and bleeding in a 73-year-old patient with an infected and exposed
silver-coated polyester (InterGard Silver, Datascope, Montvale,
NJ) axillary unifemoral bypass graft in the right groin. Central
vascular reconstruction was not possible because of high cardiac
risks, and the left groin was unaccesible because of a low-grade
infection after reconstruction for a pseudoaneurysm that followed
iliacofemoral prosthetic surgery.
The patient presented 10 days after axillofemoral bypass with
a deep infection of the right groin. Staphylococcus aureus was
cultured and treated with intravenous antibiotics. No systemic sign
of sepsis existed. We performed a wound débridement and started
VAC therapy that same day with constant suction of 75 mmHg. A
polyvinylalcohol sponge was used because of its less ingrowth
characteristics compared with polyurethane sponges.
On the third day progressive swelling developed in the pa-
tient’s right groin and the vacuum system was occluded after
collecting 1 liter of blood. An emergency operation revealed
disruption of the distal anastomosis. We removed the bypass, used
venous patches to close the proximal and distal anastomosis, and in
a second operation, we had to perform an above-knee amputation
for severe ischemia of the leg.
We describe this case to alert readers that while VAC therapy is
often successful, it does not always control infection and can be
associated with anastomotic disruption.
Victor Brehm, MD
Rijnland Hospital Leiderdorp
Leiderdorp, The Netherlands
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We would like to thank Dr. Brehm for his kind remarks about
our paper regarding the use of vacuum-assisted closure (VAC) for
graft preservation in patients with exposed grafts. His letter ad-
dresses the possibility of arterial “blow-out” associated with use of
VAC, a complication we have (fortunately) not seen. Understand-
ing this concern, we will emphasize a number of points that may
reduce the risk of this life-threatening complication.
1. The importance of controlling infectionwith radical débridement,
culture-directed antibiotics, and serial wound explorations cannot
be overemphasized, as this is a prerequisite for graft preservation.
This is not only true for VAC systems but also for those in whom
muscle flap is contemplated. Graft preservation (with VAC or
muscle flaps) cannot be accomplished unless the bacterial load is
minimized. Case selection for graft preservation is extremely im-
portant, and graft removal should be consideredwhen eradication
of infection is not achieved.
2. We do not advocate starting VAC therapy early after the initial
débridement. In our series, VAC was begun on the third day
after débridement in those with an exposed anastomosis. Before
VAC placement, we use silver-containing gel for dressing
changes. This allows daily inspection of the wound to assess the
adequacy of débridement and ensure lack of a significant infec-
tious process. The presence of VAC in the wound does not
allow close monitoring of the wounds in this early period.
3. Once the VAC is placed, we use nonadhering dressings around
the anastomosis and personally inspect the wound during each
VAC change. The nonadherent dressing is used until the anas-
tomosis is no longer visible in the wound. This practice stems
from our hypothetical concern about direct trauma to the
anastomosis from the VAC device. However, we believe that
the most likely cause of arterial disruption associated with groin
wound infections is arterial infection. As Dr Brehm concludes
that the arterial blow-out in his patient was “possibly . . . due to
the suction of the VAC system,” use of a nonadherent dressing
around the anastomosis may reduce the risk of direct arterial
trauma and subsequent bleeding.
We agree with Dr Brehm’s conclusion that the VAC should be
used in highly selected patients with infected and exposed grafts.
Because anastomotic blowout is a possible complication of at-
tempted graft preservation with exposed anastomosis, these pa-
tients should be carefully monitored in the acute care setting and
discharged only after the anastomosis is fully covered with granu-
lation tissue with no evidence of infection.
Hasan H Dosluoglu, MD
Dennis K Schimpf, MD
Raymond Schultz, MD
Gregory S. Cherr, MD, RVT
Department of Surgery
SUNY at Buffalo
Buffalo, New York
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Regarding “Current results of open surgical repair of
descending thoracic aortic aneurysms”
I read with great interest the review article on the surgical
treatment of descending thoracic aortic aneurysms (TAAs) by
Black and Cambria1 describing the advantages of the various
surgical strategies on the surgical treatment of TAAs. However, I
was surprised not to see included and cited the technique that
offered the best results on the prevention of spinal cord ischemia.
In 1999, Biglioli et al2 proposed the “quick, simple clamping
technique” for the replacement of descending aorta to prevent
spinal cord injury. In 49 consecutive patients, they had 0 paraple-
gia; however, in the groups of “selective atriodistal bypass” (66
patients) and “simple clamping technique” (28 patients), they had
4.5% and 14.3% incidence of paraplegia, respectively. They also
demonstrated that the aortic cross-clamping time is the most
important factor correlated to spinal cord injury. Indeed, the
proposed technique aims in the reduction of aortic clamping under
the crucial 25 minutes.
Many other authors3 found that spinal cord ischemic time
30 minutes has been considered a critical event, regardless of the
spinal cord protective techniques employed, and all spinal-
protective approaches, including deep hypothermia and circulatory
arrest, intercostals arteries reimplantation, cerebrospinal fluid
drainage, distal circulatory support, left-heart by-pass, could not
completely eliminate the occurrence of paraplegia. In the article by
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